Research programme: complement membrane attack complex inhibitors - RegenesanceAlternative Names: MAC-i
Latest Information Update: 16 Jul 2016
At a glance
- Originator Regenesance
- Mechanism of Action Complement membrane attack complex inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Peripheral nervous system diseases
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Peripheral-nervous-system-diseases in Netherlands
- 30 Nov 2009 Preclinical trials in Peripheral nerve disorders in Netherlands (unspecified route)